AVAILABILITY OF VACCINATION AGAINST COVID-19: WORLD EXPERIENCE AND THE SITUATION IN BELARUS

© 2022 Nikolay Vladimirovich GOLOBORODKO, Ekaterina Ivanovna DUNAEVA

2022 – № 1(23)


DOI: https://doi.org/10.33876/2224-9680/2022-1-23/05
Citation link:

Goloborodko N.V., Dunaeva Ye.I. (2022) Dostupnost’ vaktsinatsii ot COVID-19: mirovoy opyt i situatsiya v Belarusi [Availability of Vaccination Against Covid-19: World Experience and the Situation in Belarus], Meditsinskaya antropologiya i bioetika [Medical Anthropology and Bioethics], № 1(23).


Nikolay Vladimirovich Goloborodko

Candidate of Medical Sciences,

Associate Professor of the Department of Pediatrics

Belarusian Medical Academy

of Postgraduate Education

(Minsk, Republic of Belarus)

https://orcid.org/0000-0003-1912-5471

E-mail: halabarodzka@gmail.com


Ekaterina Ivanovna Dunaeva

Senior lecturer of the Department of Paediatrics

.

Belarusian Medical Academy of Postgraduate Education

.

https://orcid.org/0000-0003-0779-925X

.

E-mail: dunayevaekaterina@gmail.com


Keywords: COVID-19, vaccines, Belarus, access, affordability, vaccination coverage, national immunization policy, low threshold services, emergency use authorization, COVAX mechanism, projected needs

Abstract: The conditions that affect the availability of COVID-19 vaccination are listed. A brief description of the leading COVID-19 vaccines and their manufacturers is given. An analysis of the current access to COVID-19 vaccines as well as to routine vaccination globally and in Belarus is presented. The ways to increase access to vaccines are considered: the WHO-recommended mechanism of emergency use authorization of vaccines and its implementation in Belarus, the COVAX mechanism to ensure equal access to vaccines throughout the countries with different income level, grading the priority of providing vaccines to certain categories of the people, as well as lowering the services threshold. Projected ongoing needs of COVID-19 vaccines are discussed, as well as the prospects of further use the experience of combating the pandemic (including developed new technological platforms for the production of vaccines, accelerated launch of vaccines on the market, cross-country cooperation) in solving other challenges in the field of medicine, including eliminating the global shortage of routine vaccines.

References

Maxmen, A. (2022) Unseating big pharma: the radical plan for vaccine equity, Nature, Vol. 607. Nо7918, p. 226–233.

Offit, P.A. (2022) Covid-19 Boosters – Where from Here? New Engl J Med, Vol. 386, p.1661–1662.

Schlake, T., Thess, A., Fotin-Mleczek, M., Kallen, K.J. (2012) Developing mRNA-vaccine technologies, RNA biology, Vol. 90. Nо 11, p. 1319–1330.

Thomson, A., Robinson, K., Vallée-Tourangeau, G. (2016) The 5As: A practical taxonomy for the determinants of vaccine uptake, Vaccine, Vol. 34 No.8, p. 1018–1024.